Evidence map›Paper›PMID 39766891›Full record

ArticleGenes2024

The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids.

Nobuaki Kobayashi, Seigo Katakura, Nobuhiko Fukuda, Kohei Somekawa, Ayami Kaneko, Takeshi Kaneko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nobuaki KobayashiDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.ORCID 0000-0002-7064-320X
Seigo KatakuraDepartment of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Yokohama 241-0815, Japan.
Nobuhiko FukudaDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.
Kohei SomekawaDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.
Ayami KanekoDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.
Takeshi KanekoDepartment of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BevacizumabCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionErbB ReceptorsLung NeoplasmsMicroRNAsMutationOrganoidsProtein Kinase InhibitorsCell Line, TumorGene Expression Regulation, NeoplasticHumansTumor MicroenvironmentZinc Finger E-box-Binding Homeobox 1BevacizumabEGFR protein, humanErbB ReceptorsMicroRNAsMIRN200 microRNA, humanProtein Kinase InhibitorsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1drug resistanceEpidermal Growth Factor Receptor (EGFR) mutationsepithelial–mesenchymal transition (EMT)non-small-cell lung cancer (NSCLC)organoid models

Identifiers

PMID39766891
PMCPMC11675723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.